DBV Technologies Correlations
| DBVT Stock | USD 10.00 0.29 2.99% |
The current 90-days correlation between DBV Technologies and Inventiva Sa is -0.05 (i.e., Good diversification). The correlation of DBV Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
DBV Technologies Correlation With Market
Significant diversification
The correlation between DBV Technologies and DJI is 0.09 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding DBV Technologies and DJI in the same portfolio, assuming nothing else is changed.
Moving together with DBV Stock
Moving against DBV Stock
| 0.36 | FATE | Fate Therapeutics | PairCorr |
| 0.54 | PG | Procter Gamble | PairCorr |
| 0.4 | 07274NBG7 | BAYNGR 5 15 | PairCorr |
| 0.39 | KO | Coca Cola Earnings Call This Week | PairCorr |
Related Correlations Analysis
| -0.4 | -0.05 | 0.7 | 0.8 | 0.64 | GHRS | ||
| -0.4 | 0.02 | -0.45 | -0.25 | -0.08 | IVA | ||
| -0.05 | 0.02 | 0.26 | 0.09 | 0.19 | GNFT | ||
| 0.7 | -0.45 | 0.26 | 0.68 | 0.77 | CTMX | ||
| 0.8 | -0.25 | 0.09 | 0.68 | 0.78 | ACRS | ||
| 0.64 | -0.08 | 0.19 | 0.77 | 0.78 | SYRE | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between DBV Stock performing well and DBV Technologies Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze DBV Technologies' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GHRS | 3.96 | 0.97 | 0.26 | 1.00 | 3.26 | 8.13 | 22.55 | |||
| IVA | 3.21 | 0.13 | 0.00 | (2.02) | 3.61 | 6.78 | 18.33 | |||
| GNFT | 2.86 | 0.17 | 0.02 | 0.90 | 3.79 | 6.37 | 20.82 | |||
| CTMX | 7.37 | 2.27 | 0.42 | 0.54 | 5.35 | 13.85 | 145.00 | |||
| ACRS | 3.23 | 0.46 | 0.11 | 0.85 | 3.25 | 8.18 | 19.29 | |||
| SYRE | 3.15 | 0.23 | 0.07 | 0.29 | 4.05 | 7.10 | 21.28 |
DBV Technologies Corporate Management
| PharmD D | Chief Officer | Profile | |
| Joseph Becker | VP Communications | Profile | |
| Sbastien Robitaille | Chief Officer | Profile | |
| Wence Agbotounou | Chief Clinical Trial Officer | Profile | |
| Caroline Daniere | Chief Staff | Profile | |
| Daniel Tass | CEO Director | Profile |